INmune Bio Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
2.160
-0.070 (-3.14%)
At close: Aug 20, 2026, 4:00 PM EDT
2.170
+0.010 (0.48%)
After-hours: Aug 20, 2026, 7:04 PM EDT

INmune Bio Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
-0.050.010.160.370.18
Revenue Growth
-257.14%-90.97%-58.56%106.63%1545.45%
Gross Profit
-0.050.010.160.370.18
Selling, General & Admin
10.1410.269.489.629.268.79
Research & Development
10.0520.6633.1720.2717.0720.54
Operating Expenses
20.230.9242.6529.926.3329.33
Operating Income
-20.2-30.87-42.64-29.74-25.95-29.15
Interest Expense
---0.79-2.28-2.01-
Interest & Investment Income
1.20.91.3---
Other Non Operating Income (Expenses)
-0.02-0.050.042.010.67-1.19
EBT Excluding Unusual Items
-19.02-30.02-42.08-30.01-27.3-30.34
Other Unusual Items
0.60.6----
Pretax Income
-18.42-45.93-42.08-30.01-27.3-30.34
Net Income
-18.42-45.93-42.08-30.01-27.3-30.34
Net Income to Common
-18.42-45.93-42.08-30.01-27.3-30.34
Net Income Growth
------
Shares Outstanding (Basic)
272520181816
Shares Outstanding (Diluted)
272520181816
Shares Change
20.73%24.13%10.92%0.30%11.14%34.55%
EPS (Basic)
-0.69-1.86-2.11-1.67-1.52-1.88
EPS (Diluted)
-0.69-1.86-2.11-1.67-1.52-1.88
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-15.73-23.62-33.36-11.98-22.69-28.5
Free Cash Flow Per Share
-0.59-0.95-1.67-0.67-1.26-1.77
Gross Margin
-100.00%100.00%100.00%100.00%100.00%
Operating Margin
--61738.00%-304535.71%-19187.74%-6938.77%-16106.63%
Profit Margin
--91866.00%-300585.71%-19360.00%-7299.20%-16762.43%
Free Cash Flow Margin
--47248.00%-238292.86%-7729.03%-6065.77%-15748.07%
EBITDA
--30.79----
D&A For EBITDA
-0.08----
EBIT
-20.2-30.87-42.64-29.74-25.95-29.15
SEC Filings: 10-K · 10-Q